YECO
EV Biologics, Inc. is a biotechnology enterprise focused on the commercial advancement of extracellular vesicles (EVs), utilizing them as biological agents for diagnostic and therapeutic applications. The company capitalizes on its proprietary, versatile EV platform to engineer innovative vaccines, treatments, and potential cures. Beyond EVs, it also dedicates efforts to cultivating human mesenchymal and other stem cells, as well as various cell-derived products, to address the needs of the cosmetic and biopharmaceutical industries. Founded in 2011, the firm was originally known as Yulong Eco-Materials Limited until its rebranding to EV Biologics, Inc. in August 2020, and it operates from its headquarters in Cheyenne, Wyoming.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q2 | -0.00 | $0 | — |
| 2025 Q1 | 0.00 | $48,000 | — |
| 2024 Q4 | 0.00 | $40,344 | $370 |
| 2024 Q3 | 0.01 | $138,018 | -$3,280 |
| 2024 Q2 | -0.02 | $0 | -$17,579 |
| 2024 Q1 | -0.02 | $0 | -$106,130 |
| 2023 Q4 | -0.02 | $48,900 | $20M |
| 2023 Q3 | -0.05 | $0 | -$23M |